Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations

Glioblastoma (GBM) is the most aggressive tumor type whose resistance to conventional treatment is mediated, in part, by the angiogenic process. New treatments involving the application of nanoformulations composed of encapsulated drugs coupled to peptide motifs that direct drugs to specific targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Nery de Albuquerque Rego, Gabriel, da Hora Alves, Arielly, Penteado Nucci, Mariana, Bustamante Mamani, Javier, Anselmo de Oliveira, Fernando, Gamarra, Lionel Fernel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349965/
https://www.ncbi.nlm.nih.gov/pubmed/32599834
http://dx.doi.org/10.3390/ijms21124490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349965/
https://www.ncbi.nlm.nih.gov/pubmed/32599834
http://dx.doi.org/10.3390/ijms21124490

Ejemplares similares